HK inno.N, a trailblazer in pharmaceuticals, celebrates a pivotal moment as its acclaimed GERD medication, K-CAB (tegoprazan), debuts in Australia and New Zealand.
Through an exclusive agreement with Southern XP, a trusted distributor with over two decades of regional expertise, K-CAB 50mg and 25mg formulations are now set to address unmet medical needs in these dynamic markets.
Global Expansion Momentum
Valued collectively at 22 trillion won ($15 billion) as of 2023, the pharmaceutical markets of Australia and New Zealand offer immense potential for GERD and peptic ulcer solutions, a niche pegged at 150 billion won.
Kwak Dal-won, CEO of HK inno.N, remarked, “K-CAB’s success underscores the growing global recognition of Korean pharmaceuticals. By 2028, we aspire to enter 100 countries, establishing K-CAB as a global benchmark.”
Why K-CAB Leads the Pack
As Korea’s 30th new drug, K-CAB, a P-CAB (Potassium-Competitive Acid Blocker), offers unparalleled advantages: Rapid Action: Relief begins within an hour of ingestion.
Ease of Use: A quick-dissolving formulation eliminates the need for swallowing.
Long-Term Assurance: Proven safety and efficacy over extended periods.
These innovations have fueled K-CAB’s success across 48 countries, with a strong presence in key markets like Korea, the U.S., and China.
Market Leadership in Korea
Domestically, K-CAB has reigned as the top peptic ulcer drug for five consecutive years. Sales from January to November 2024 alone surpassed 177.7 billion won, a testament to its unrivaled efficacy and demand.
Vision 2028: A Global Standard
HK inno.N’s relentless commitment to innovation and strategic expansion positions K-CAB as a formidable contender in the GERD treatment landscape. The latest milestone in Australia and New Zealand is a stepping stone toward achieving its bold vision of reaching 100 countries by 2028.
